EMA Recommends Granting a Marketing Authorisation for Nirogacestat By Ogkologos - July 3, 2025 183 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of adult patients with progressing desmoid tumours Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR Study Finds the Cost of Treating Metastatic Breast Cancer Could More... August 3, 2021 Breakthrough SARS-CoV-2 Infection Following COVID-19 Vaccination in Patients with Cancer January 12, 2022 Her Massive Weight Loss Helped Her Feel A Lump In Her... January 24, 2020 Tough questions for tough times in clinical research April 29, 2022 Load more HOT NEWS Imetelstat Shows Durable Transfusion Independence and Disease-Modifying Activity in Heavily Transfused... Inhibition of GDF-15 with Ponsegromab Results in Increased Weight Gain and... ESMO Gynaecological Cancers Congress 2025, Vienna, Austria, 19-21 June Real-World Patients with Cancer Show Lower Survival Times and Treatment-Associated Survival...
